drugset / Trial / NCT06514001
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Timeline
- Start
- 2025-03-07
- Primary completion
- 2026-09
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMDX-2011P | Diagnostic / imaging agent | 100 mg | Intravenous |